Posts by Replicor

MONTREAL, November 14th, 2023 – Replicor Inc. announced the disclosure of updated clinical data from the compassionate use of REP 2139-Mg and updated mechanistic data on the direct acting activity of REP 2139 in HDV infection at the annual meeting of the American Association for the Study of Liver Diseases (AASLD) November 10-14, 2023 in…

MONTREAL, October 2nd, 2023 – Replicor Inc. announced the presentation of clinical data from the compassionate use of REP 2139-Mg in its first Canadian patient with HBV / HDV / HIV co-infection at the 2023 Special Topic Conference on HBV held by the Canadian Association for the Study of the Liver, September 29 – October…

MONTREAL, September 25th, 2023 – Replicor Inc. announced the presentation of new data describing the direct acting activity of REP 2139 against HDV replication at the 2023 International Molecular Biology of HBV meeting, held from September 19-23, 2023 in Kobe, Japan (see here). This new data, generated in the lab of Dr. Massimo Levrero at…

MONTREAL, July 24th, 2023 – Replicor Inc. announced the publication of modelling analysis of HBsAgresponses in its REP 401 study linking rapid HBsAg loss to functional cure of HBV.This new study, published in Hepatology Communications (see here), is part of an ongoing collaborationwith Dr. Harel Dahari’s team at Loyola University (Chicago, USA) to analyze clinical…

MONTREAL, June 28th, 2023 – Replicor Inc. presented its latest clinical data on the compassionate use of REP 2139-Mg in HBV / HDV co-infection at the 2023 Annual Meeting of the European Association for the Study of the Liver (EASL) in Vienna, Austria (see here). Dr. Christiane Stern (Hôpital Beaujon, Clichy, France) presented updated clinical…

MONTREAL, May 10th, 2023 – Replicor Inc. had its latest clinical data on NAPs in HBV and HDV infection highlighted at the 2023 Digestive Disease Weekly Meeting held May 6-9th in Chicago, IL, USA (see here). Dr. Christiane Stern (Hôpital Beaujon, Clichy, France) presented Replicor’s latest clinical data on the safety and tolerability of TDF…

MONTREAL, May 1st, 2023 – Replicor Inc., presented updated clinical data in HBV and HDV infection in three oral presentations at the 2023 Global Hepatitis Summit held April 24th – 28th in Paris France (see here). In a late breaking oral presentation, Dr. Andrew Vaillant, CSO of Replicor Inc. presented new follow-up data from the…

MONTREAL, February 20th, 2023 – Replicor Inc., presented updated clinical data in HBV and HDV infection in a greatly expanded cohort of patients receiving compassionate access to REP 2139-Mg at the 2023 annual meeting of the Asia Pacific Association for the Study of the Liver (APASL) held February 15th  – 19th, 2023 in Taipei, Taiwan…

MONTREAL, October 12th, 2022 – Replicor Inc., presented data indicating the broad-spectrum antiinflammatory properties of REP 2139 at the 2022 Delta Cure Meeting held October 6-7, 2022 in Milan, Italy (see here). Target interaction of nucleic acid polymers (NAPs) occurs via a unique drug interface (see here) previously shown to be present in type 1…

MONTREAL, September 22nd 2022 – Replicor Inc., presented updated clinical data from its expanded compassionate use program for treating chronic HBV/HDV co-infection in cirrhotic patients at the 2022 International HBV Meeting held September 18 – 21, 2022 in Paris (see here). Replicor’s expanded use program in France now includes 5 patients with advanced HBV/HDV co-infection,…